{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:50:39Z","timestamp":1760079039947},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1994,1,1]],"date-time":"1994-01-01T00:00:00Z","timestamp":757382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1994]]},"DOI":"10.1007\/bf00686643","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T09:18:03Z","timestamp":1101719883000},"page":"174-178","source":"Crossref","is-referenced-by-count":1,"title":["A phase I\/II study of 4?-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients"],"prefix":"10.1007","volume":"35","author":[{"given":"Herbert","family":"St\ufffdger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bauernhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinand","family":"Ploner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Derstvenscheg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Steindorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martini","family":"Wilders-Truschnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Kuss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hellmut","family":"Samonigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","series-title":"Proceedings of the Symposium on Development of Folates and Folic Acid Antagonists in Cancer Chemotherapy","first-page":"5","volume-title":"A phase II trial for the treatment of metastatic breast cancer with 5-fluorouracil and leucovorin","author":"JC Allegra","year":"1986","unstructured":"Allegra JC, Sholar PW, Drake JC, Bagley C, Lippman ME, Chabner BA (1986) A phase II trial for the treatment of metastatic breast cancer with 5-fluorouracil and leucovorin (abstract). Proceedings of the Symposium on Development of Folates and Folic Acid Antagonists in Cancer Chemotherapy. Innisbrook, Tarpon Springs, p 5"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0360-3016(83)90286-9","volume":"9","author":"G Bonnadonna","year":"1983","unstructured":"Bonnadonna G, Valagussa P (1983) Chemotherapy of breast cancer. Current views and results. Int J Radiat Oncol Biol Phys 9: 279?297","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/jnci\/55.6.1265","volume":"35","author":"SK Carter","year":"1975","unstructured":"Carter SK (1975) Adriamycin, a review. J Natl Cancer Inst 35: 1265","journal-title":"J Natl Cancer Inst"},{"key":"CR4","series-title":"Proceedings of the 13th International Congress of Chemotherapy","first-page":"15","volume-title":"Cardiotoxicity and alopecia of 12 different anthracyclines in the golden hamster model","author":"D Dantchev","year":"1983","unstructured":"Dantchev D, Bourut C, Maral R, Math\u00e9 G (1983) Cardiotoxicity and alopecia of 12 different anthracyclines in the golden hamster model. Proceedings of the 13th International Congress of Chemotherapy. Spitzy, Karrer, Vienna, pp 15?19"},{"key":"CR5","first-page":"733","volume":"11","author":"H Fujita","year":"1984","unstructured":"Fujita H (1984) Chemical modification of anticancer agents from the viewpoint of their pharmacokinetics. Gan to Kagaku Ryoho 11: 733?740","journal-title":"Gan to Kagaku Ryoho"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F","volume":"39","author":"JL Hayward","year":"1977","unstructured":"Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289","journal-title":"Cancer"},{"key":"CR7","first-page":"914","volume-title":"Cancer, principles and practice of oncology","author":"S Hellman","year":"1982","unstructured":"Hellman S, Harris J, Canellos GP, et al (1982) Cancer of the breast. In: De Vita V, Hellman S, Rosenberg S (eds) Cancer, principles and practice of oncology. Lippincott, Philadelphia, pp 914?970"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM198001033020104","volume":"302","author":"IC Henderson","year":"1980","unstructured":"Henderson IC, Cancellos GP (1980) Cancer of the breast ? the past decade. N Engl J Med 302: 17?30; 78?90","journal-title":"N Engl J Med"},{"key":"CR9","first-page":"34","volume":"14","author":"IC Henderson","year":"1987","unstructured":"Henderson IC, Hayes DF, Come S, et al (1987) New agents and new medical treatments for advanced breast cancer. Semin Oncol 14: 34?64","journal-title":"Semin Oncol"},{"key":"CR10","first-page":"101","volume":"2","author":"B Hoogstraten","year":"1979","unstructured":"Hoogstraten B, Fabian C (1979) A reappraisal of single drugs in advanced breast cancer. Cancer Clin Trials 2: 101?109","journal-title":"Cancer Clin Trials"},{"key":"CR11","first-page":"368","volume":"3","author":"K Kimura","year":"1986","unstructured":"Kimura K (1986) A phase II study of (2?R)-4?-O-tetrahydropyranyl-adriamycin (THP) in patients with hematological malignancies. Jpn J Cancer Chemother 3: 368?375","journal-title":"Jpn J Cancer Chemother"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1200\/JCO.1986.4.5.685","volume":"4","author":"D Machover","year":"1986","unstructured":"Machover D, Goldschmidt E, Chollet P et al (1986) Treatment of advanced colorectal and gastric carcinoma with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685?696","journal-title":"J Clin Oncol"},{"key":"CR13","first-page":"542","volume":"13","author":"H Majima","year":"1986","unstructured":"Majima H, Iguchi H, Tone H (1986) Pharmacokinetics studies on THP-ADM (Tetrahydropyranyl-adriamycin). Jpn J Cancer Chemother 13: 542?548","journal-title":"Jpn J Cancer Chemother"},{"key":"CR14","first-page":"135","volume":"4","author":"G Marini","year":"1985","unstructured":"Marini G, Marcipati P, Zaniboni A, Cervi GC, Gorni F, Simoncini E (1985) Treatment of advanced breast cancer with 5-fluorouracil and high dose folinic acid: preliminary results. Chemiotherapia 4: 135?138","journal-title":"Chemiotherapia"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00390491","volume":"114","author":"AB Miller","year":"1988","unstructured":"Miller AB, Scheulen ME, Kleeberg UR, et al (1988) Phase I study of pirarubicin. J Cancer Res Clin Oncol 114: 91?94","journal-title":"J Cancer Res Clin Oncol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1200\/JCO.1987.5.10.1559","volume":"5","author":"N Petrelli","year":"1987","unstructured":"Petrelli N, Herrera L, Rustum YM, et al (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and highdose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559?1565","journal-title":"J Clin Oncol"},{"key":"CR17","first-page":"1060","volume":"13","author":"T Saito","year":"1986","unstructured":"Saito T, Kasai Y, Wakui A, et al (1986) Phase II study of (2?R)-4?-O-tetrahydropyranyladriamycin. Jpn J Cancer Chemother 13: 1060?1069","journal-title":"Jpn J Cancer Chemother"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF02897233","volume":"26","author":"H Samonigg","year":"1990","unstructured":"Samonigg H, Kasparek AK, Stoger H, et al (1990) 4?-O-Tetrahydropyranyl-doxorubicin in advanced breast cancer: a phase II study. Cancer Chemother Pharmacol 26: 293?296","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000417970","volume":"37","author":"W Scheithauer","year":"1989","unstructured":"Scheithauer W, Samonigg H, Depisch D, et al (1989) Pirarubicin (4?-O-tetrahydropyranyl-doxorubicin) for treatment of metastatic breast cancer. Contrib Oncol 37: 89?93","journal-title":"Contrib Oncol"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.1989.7.7.890","volume":"7","author":"SM Swain","year":"1989","unstructured":"Swain SM, Lippman ME, Eagan EF, Drake JC, Steinberg SM, Allegra CJ (1989) Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Cin Oncol 7: 890?899","journal-title":"J Cin Oncol"},{"key":"CR21","first-page":"319","volume":"6","author":"DC Tormey","year":"1975","unstructured":"Tormey DC (1975) Adriamycin (NSC-123127) in breast cancer: an overview of studies. Cancer Chemother Rep 6: 319?327","journal-title":"Cancer Chemother Rep"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/1097-0142(19821001)50:7<1235::AID-CNCR2820500703>3.0.CO;2-L","volume":"50","author":"DC Tormey","year":"1982","unstructured":"Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, Dewys W, Perlia C, Rice MA (1982) Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50: 1235?1244","journal-title":"Cancer"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.7164\/antibiotics.32.1082","volume":"10","author":"H Umezawa","year":"1979","unstructured":"Umezawa H, Takahashi Y, Kinoshita M et al (1979) Tetrahydropyranyl derivates of daunomycin and adriamycin. J Antibiot (Tokyo) 10: 1082?1084","journal-title":"J Antibiot (Tokyo)"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Hoff Von","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, et al (1979) Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 91: 710?717","journal-title":"Ann Intern Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686643.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00686643\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T11:15:24Z","timestamp":1585998924000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00686643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1994]]}},"alternative-id":["BF00686643"],"URL":"https:\/\/doi.org\/10.1007\/bf00686643","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994]]}}}